OCCIDENT
We invest in deep tech start-ups with a focus on spin-offs originating from
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
As a venture capital investor, we support start-ups from the seed stage onwards and enable founding teams to achieve outstanding results. With a strong entrepreneurial mindset, we invest our own money and make decisions based on sustainable potential for success.
Portfolio
Co-operation with the founding teams of our portfolio companies motivates and inspires us every day. We are energized by their passion and drive, and the often very intense exchange spurs us on to tackle challenges together.
Want to learn more about OCCIDENT?
OCCIDENT in numbers
Portfolio News
Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.
Resistell is publishing in Nature!
A peer-reviewed article on Resistell’s rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.
Follow-on investment in Tubulis
OCCIDENT is excited to announce its participation in Tubulis’ €128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest.
The Science Investor.
The OCCIDENT Team
Curious, perceptive, grounded and courageous, yet also humorous and team-oriented – that is the OCCIDENT team. As experts in our field, we know exactly what we are doing.